International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8079344
Original Article
YKL-40 as Inflammatory Marker in Reference to hs CRP in CKD Individuals with Uremic Toxicity to Diagnose the Cardio Vascular Events
 ,
 ,
 ,
 ,
 ,
 ,
Published
June 25, 2023
Abstract

CKD one of the non-communicable diseases was forecasted to be raised in the cases, in which there is rise in uraemic toxins which may leads to secondary complication, hence we intended to study the inflammation due to uraemic toxicity. The study subjects were picked randomly. The basic information, the patient history was collected and blood samples were drawn after obtaining a written consent form. The patients were grouped into four different groups as, Group I (controls) contain normal healthy individuals free from all the systemic ailments (n=50). Group II contains individuals with CKD stage 1 &2 (n=50) Group III contains individuals with CKD stage 3, 4 & 5 (n=50). Group IV contains individuals with Hemodialysis (n=50). The study protocol was approved by the Institutional Ethics Committee. Biochemical parameters like fasting blood glucose, RFT, uric acid and inflammatory biomarkers were analyzed. Although inflammation may have protective, but in hemodialysis the inflammation does persist which can lead to development of CV events. In this regard we suggest to estimate the CRP levels along with YKL-40 to decide the doses of dialysis to reduce the inflammation as a conceptive therapy to reduce the CV events.

Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
1591 Views
38 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved